Abstract Coronavirus disease-2019 (COVID-19) represents a global public health
nightmare. The “cytokine storm,” the most prominent underlying pathophysiologic …

Background With potential antiviral and anti‐inflammatory properties, Janus kinase (JAK)
inhibitors represent a potential treatment for symptomatic severe acute respiratory syndrome …

Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of Janus kinase (JAK) inhibitors for …

Background Cytokine storm observed in patients with severe Coronavirus Disease 2019
(COVID-19) contributes to poor clinical outcomes and increased mortality. Janus kinases …

Background The evidence of using JAK inhibitors among hospitalized patients with COVID-
19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of …

Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …

We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine
storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been …

Janus kinase (JAK) inhibitors for the treatment of hospitalised patients with COVID-19 have
been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib …

Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has
emerged as a once-in-a-century pandemic, having already infected over 63 million people …